Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar 1;5(3):e221048.
doi: 10.1001/jamanetworkopen.2022.1048.

Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial

Girish N Nadkarni  1   2 , Kezhen Fei  3   4 , Michelle A Ramos  3   4 , Diane Hauser  5 , Emilia Bagiella  3 , Stephen B Ellis  2 , Saskia Sanderson  2 , Stuart A Scott  2   6   7 , Tatiana Sabin  3   4 , Ebony Madden  8 , Richard Cooper  9 , Martin Pollak  10 , Neil Calman  4   5 , Erwin P Bottinger  1   2   11 , Carol R Horowitz  2   3   4
Affiliations
Randomized Controlled Trial

Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial

Girish N Nadkarni et al. JAMA Netw Open. .

Abstract

Importance: Risk variants in the apolipoprotein L1 (APOL1 [OMIM 603743]) gene on chromosome 22 are common in individuals of West African ancestry and confer increased risk of kidney failure for people with African ancestry and hypertension. Whether disclosing APOL1 genetic testing results to patients of African ancestry and their clinicians affects blood pressure, kidney disease screening, or patient behaviors is unknown.

Objective: To determine the effects of testing and disclosing APOL1 genetic results to patients of African ancestry with hypertension and their clinicians.

Design, setting, and participants: This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018. Patients were randomly assigned to undergo immediate (intervention) or delayed (waiting list control group) APOL1 testing in a 7:1 ratio. Statistical analysis was performed from May 1, 2018, to July 31, 2020.

Interventions: Patients randomly assigned to the intervention group received APOL1 genetic testing results from trained staff; their clinicians received results through clinical decision support in electronic health records. Waiting list control patients received the results after their 12-month follow-up visit.

Main outcomes and measures: Coprimary outcomes were the change in 3-month systolic blood pressure and 12-month urine kidney disease screening comparing intervention patients with high-risk APOL1 genotypes and those with low-risk APOL1 genotypes. Secondary outcomes compared these outcomes between intervention group patients with high-risk APOL1 genotypes and controls. Exploratory analyses included psychobehavioral factors.

Results: Among 2050 randomly assigned patients (1360 women [66%]; mean [SD] age, 53 [10] years), the baseline mean (SD) systolic blood pressure was significantly higher in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes and controls (137 [21] vs 134 [19] vs 133 [19] mm Hg; P = .003 for high-risk vs low-risk APOL1 genotypes; P = .001 for high-risk APOL1 genotypes vs controls). At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes (6 [18] vs 3 [18] mm Hg; P = .004) and controls (6 [18] vs 3 [19] mm Hg; P = .01). At 12 months, there was a 12% increase in urine kidney disease testing among patients with high-risk APOL1 genotypes (from 39 of 234 [17%] to 68 of 234 [29%]) vs a 6% increase among those with low-risk APOL1 genotypes (from 278 of 1561 [18%] to 377 of 1561 [24%]; P = .10) and a 7% increase among controls (from 33 of 255 [13%] to 50 of 255 [20%]; P = .01). In response to testing, patients with high-risk APOL1 genotypes reported more changes in lifestyle (a subjective measure that included better dietary and exercise habits; 129 of 218 [59%] vs 547 of 1468 [37%]; P < .001) and increased blood pressure medication use (21 of 218 [10%] vs 68 of 1468 [5%]; P = .005) vs those with low-risk APOL1 genotypes; 1631 of 1686 (97%) declared they would get tested again.

Conclusions and relevance: In this randomized clinical trial, disclosing APOL1 genetic testing results to patients of African ancestry with hypertension and their clinicians was associated with a greater reduction in systolic blood pressure, increased kidney disease screening, and positive self-reported behavior changes in those with high-risk genotypes.

Trial registration: ClinicalTrials.gov Identifier: NCT02234063.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Nadkarni reported receiving personal fees from Renalytix, being a cofounder and having equity in Renalytix, and being a member of the scientific advisory board of Renalyti and a cofounder of Pensieve Health. Mss Ramos and Hauser and Dr Horowitz reported receiving grants from the National Human Genome Research Institute (NHGRI)/National Institutes of Health (NIH) during the conduct of the study. Dr Bagiella reported receiving grants from the NIH during the conduct of the study. Dr Scott reported being a paid consultant of Sema4. Dr Pollak reported receiving grants and personal fees from Vertex and having equity in Apolo1Bio outside the submitted work; in addition, Dr Pollak had a patent for US20200399702A1 issued. No other disclosures were reported.

Figures

Figure.
Figure.. Enrollment and Randomization of Study Participants
See this image and copyright information in PMC

Comment in

  • Race, Ancestry, and Genetic Risk for Kidney Failure.
    Olabisi OA, Nicholas SB, Norris KC. Olabisi OA, et al. Am J Kidney Dis. 2022 Dec;80(6):801-804. doi: 10.1053/j.ajkd.2022.08.008. Epub 2022 Sep 12. Am J Kidney Dis. 2022. PMID: 36100174 Free PMC article. No abstract available.

References

    1. Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016;68(6):862-872. doi:10.1053/j.ajkd.2016.05.030 - DOI - PMC - PubMed
    1. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis. 1988;12(4):285-290. doi:10.1016/S0272-6386(88)80221-X - DOI - PubMed
    1. Myers OB, Pankratz VS, Norris KC, Vassalotti JA, Unruh ML, Argyropoulos C. Surveillance of CKD epidemiology in the US—a joint analysis of NHANES and KEEP. Sci Rep. 2018;8(1):15900. doi:10.1038/s41598-018-34233-w - DOI - PMC - PubMed
    1. Genovese G, Friedman DJ, Ross MD, et al. . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845. doi:10.1126/science.1193032 - DOI - PMC - PubMed
    1. Parsa A, Kao WHL, Xie D, et al. ; AASK Study Investigators; CRIC Study Investigators . APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-2196. doi:10.1056/NEJMoa1310345 - DOI - PMC - PubMed

Publication types

Associated data